Reverse cholesterol transport and hepatic osteodystrophy.
Reverse cholesterol transport and hepatic osteodystrophy.
复制标题
DOI：
10.1016/j.cmet.2022.02.007
复制
发表时间：
2022-03
期刊：
影响因子：
29
通讯作者：
M. Zaidi;T. Yuen;J. Iqbal
中科院分区：
文献类型：
--
作者：
M. Zaidi;T. Yuen;J. Iqbal
In this issue ofCell Metabolism, Lu et al. show that chronic liver disease increases the expression and activity of PP2Ac, a phosphatase that downregulates the excretion of lecithin-cholesterol aceyltransferase (LCAT). LCAT, a liver-derived enzyme, protects bone and prevents bone loss, and its lowered levels in progressive liver injury cause hepatic osteodystrophy (HOD) and worsen liver fibrosis. These discoveries open the possibility that recombinant LCAT may be a treatment for both HOD and liver fibrosis.
